î
îŒ
ãã°ã€ã³
î
Sanofi SA
SNY46.610USD
+1.470+3.26%
çµå€Â 03/26, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
112.57Bæ䟡ç·é¡
12.91çŽè¿12ã¶æPER
î
詳现æ å ± Sanofi SA äŒæ¥å
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofiâs Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Companyâs products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Sanofi SAã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãSNY
äŒç€ŸåSanofi SA
äžå Žæ¥Jul 01, 2002
æé«çµå¶è²¬ä»»è
ãCEOãHudson (Paul)
åŸæ¥å¡æ°84587
蚌åžçš®é¡Depository Receipt
決ç®ææ«Jul 01
æ¬ç€Ÿæåšå°46 Avenue de la Grande Armee
éœåžPARIS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœFrance
éµäŸ¿çªå·75017
é»è©±çªå·33153774000
ãŠã§ããµã€ãhttps://www.sanofi.com/
äŒæ¥ã³ãŒãSNY
äžå Žæ¥Jul 01, 2002
æé«çµå¶è²¬ä»»è
ãCEOãHudson (Paul)
Sanofi SAã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Mr. Patrick Kron
Mr. Patrick Kron
Independent Director
Independent Director
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Mr. Paul Hudson, Ph.D.
Mr. Paul Hudson, Ph.D.
Chief Executive Officer, Executive Director, Member of the Executive Committee
Chief Executive Officer, Executive Director, Member of the Executive Committee
--
--
Ms. Rachel Duan
Ms. Rachel Duan
Independent Director
Independent Director
--
--
Ms. Lise Kingo
Ms. Lise Kingo
Independent Director
Independent Director
--
--
Ms. Natalie Bickford
Ms. Natalie Bickford
Chief People Officer, Executive Vice President, Member of the Executive Committee
Chief People Officer, Executive Vice President, Member of the Executive Committee
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Mr. Thomas Triomphe
Mr. Thomas Triomphe
Executive Vice President - Vaccines, Member of the Executive Committee
Executive Vice President - Vaccines, Member of the Executive Committee
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Mr. Patrick Kron
Mr. Patrick Kron
Independent Director
Independent Director
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Mr. Paul Hudson, Ph.D.
Mr. Paul Hudson, Ph.D.
Chief Executive Officer, Executive Director, Member of the Executive Committee
Chief Executive Officer, Executive Director, Member of the Executive Committee
--
--
Ms. Rachel Duan
Ms. Rachel Duan
Independent Director
Independent Director
--
--
åçå èš³
é貚: USDæŽæ°æå»: Tue, Jan 6
é貚: USDæŽæ°æå»: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
7.99B
54.99%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
3.51B
24.18%
Europe
3.03B
20.82%
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Wed, Mar 4
æŽæ°æå»: Wed, Mar 4
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Dodge & Cox
2.34%
Fisher Investments
0.50%
Barrow Hanley Global Investors
0.29%
Managed Account Advisors LLC
0.24%
Invesco Advisers, Inc.
0.23%
ä»ã®
96.40%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Dodge & Cox
2.34%
Fisher Investments
0.50%
Barrow Hanley Global Investors
0.29%
Managed Account Advisors LLC
0.24%
Invesco Advisers, Inc.
0.23%
ä»ã®
96.40%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor/Hedge Fund
4.52%
Investment Advisor
3.67%
Research Firm
0.77%
Hedge Fund
0.25%
Bank and Trust
0.09%
Family Office
0.02%
Pension Fund
0.02%
ä»ã®
90.66%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Thu, Jan 1
æŽæ°æå»: Thu, Jan 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
1286
242.88M
9.98%
-25.07M
2025Q3
1269
251.34M
10.32%
-27.29M
2025Q2
1261
264.33M
10.86%
-14.23M
2025Q1
1286
268.29M
10.62%
-13.21M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Dodge & Cox
68.93M
2.83%
-2.79M
-3.89%
Sep 30, 2025
Fisher Investments
12.58M
0.52%
-556.62K
-4.24%
Sep 30, 2025
Barrow Hanley Global Investors
7.13M
0.29%
-153.54K
-2.11%
Sep 30, 2025
Managed Account Advisors LLC
6.44M
0.26%
-1.04M
-13.90%
Sep 30, 2025
Invesco Advisers, Inc.
5.16M
0.21%
-3.40M
-39.74%
Sep 30, 2025
Putnam Investment Management, L.L.C.
3.82M
0.16%
-310.38K
-7.52%
Sep 30, 2025
Mondrian Investment Partners Ltd.
3.64M
0.15%
+195.92K
+5.69%
Sep 30, 2025
Parametric Portfolio Associates LLC
3.48M
0.14%
-212.02K
-5.74%
Sep 30, 2025
Morgan Stanley & Co. International Plc
2.61M
0.11%
+1.82M
+231.10%
Sep 30, 2025
Boston Partners
3.68M
0.15%
-312.03K
-7.82%
Sep 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Fri, Dec 5
æŽæ°æå»: Fri, Dec 5
éæå
æ¯ç
VanEck Pharmaceutical ETF
10.04%
Invesco International Dividend Achievers ETF
3.05%
Altrius Global Dividend ETF
2.41%
Brandes US Value ETF
2.14%
Putnam Focused Large Cap Value ETF
1.9%
American Century Focused Large Cap Value ETF
1.42%
ProShares Ultra Nasdaq Biotechnology
1.33%
Invesco Nasdaq Biotechnology ETF
1.32%
Invesco ESG NASDAQ Next Gen 100 ETF
0.97%
Invesco NASDAQ Next Gen 100 ETF
0.74%
詳现ãèŠã
VanEck Pharmaceutical ETF
æ¯ç10.04%
Invesco International Dividend Achievers ETF
æ¯ç3.05%
Altrius Global Dividend ETF
æ¯ç2.41%
Brandes US Value ETF
æ¯ç2.14%
Putnam Focused Large Cap Value ETF
æ¯ç1.9%
American Century Focused Large Cap Value ETF
æ¯ç1.42%
ProShares Ultra Nasdaq Biotechnology
æ¯ç1.33%
Invesco Nasdaq Biotechnology ETF
æ¯ç1.32%
Invesco ESG NASDAQ Next Gen 100 ETF
æ¯ç0.97%
Invesco NASDAQ Next Gen 100 ETF
æ¯ç0.74%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
19.02B
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
Apr 15, 2025
SNY.NB Final Cash Dividend of gross USD 2.195331 paid on Jun 12, 2025 going ex on May 09, 2025
May 09, 2025
Jun 12, 2025
May 09, 2025
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
